Tenecteplase

Tenecteplase

220px
Systematic (IUPAC) name
Human tissue plasminogen activator
Clinical data
Trade names	Tnkase
AHFS/Drugs.com	monograph
Pregnancy cat.	?
Legal status	?
Pharmacokinetic data
Excretion	Liver
Identifiers
CAS number	105857-23-6 Y
ATC code	B01AD11
DrugBank	BTD00019
UNII	WGD229O42W N
KEGG	D02837 Y
Chemical data
Formula	C2561H3919N747O781S40
Mol. mass	58951.2 g/mol
N(what is this?)  (verify)

Tenecteplase (TNK) is an enzyme used as a thrombolytic drug.

Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain.

Tenecteplase is a recombinant fibrin-specific plasminogen activator that is derived from native t-PA by modifications at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) compared to native t-PA.

Tenecteplase is indicated in thrombolytic treatment of the acute phase of myocardial infarction (AMI) for reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms.

External links

• MedlinePlus DrugInfo uspdi-500145
• Gurbel P, Hayes K, Bliden K, Yoho J, Tantry U (2005). "The platelet-related effects of tenecteplase versus alteplase versus reteplase.". Blood Coagul Fibrinolysis 16 (1): 1–7. doi:10.1097/00001721-200501000-00001. PMID 15650539. 
• Melzer C, Richter C, Rogalla P, Borges A, Theres H, Baumann G, Laule M (2004). "Tenecteplase for the treatment of massive and submassive pulmonary embolism.". J Thromb Thrombolysis 18 (1): 47–50. doi:10.1007/s11239-004-0174-z. PMID 15744554. 
• Ohman E, Van de Werf F, Antman E, Califf R, de Lemos J, Gibson C, Oliverio R, Harrelson L, McCabe C, DiBattiste P, Braunwald E (2005). "Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial.". Am Heart J 150 (1): 79–88. doi:10.1016/j.ahj.2005.01.007. PMID 16084152. 
• De Luca G, Suryapranata H, Chiariello M (2005). "Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI. Commentary.". Evid Based Cardiovasc Med 9 (4): 284–7. doi:10.1016/j.ebcm.2005.09.021. PMID 16380055. 
• Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators (2006). "Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial.". Lancet 367 (9510): 569–78. doi:10.1016/S0140-6736(06)68147-6. PMID 16488800. 
• Bozeman W, Kleiner D, Ferguson K (2006). "Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions.". Resuscitation 69 (3): 399–406. doi:10.1016/j.resuscitation.2005.09.027. PMID 16563599. 
• Hull J, Hull M, Urso J, Park H (2006). "Tenecteplase in Acute Lower-leg Ischemia: Efficacy, Dose, and Adverse Events.". J Vasc Interv Radiol 17 (4): 629–36. doi:10.1097/01.RVI.0000202751.74625.79. PMID 16614145.